Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) received U.S. Food and Drug Administration clearance to begin a Phase 1 trial of PRT13722, moving its experimental KAT6A-targeting breast cancer drug …
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial Read More